drugset / Trial / NCT00147420
RCT of Zhi Byed 11 (ZB11) Versus Misoprostol in Tibet
Completed
848 enrolled
NICHD Global Network for Women's and Children's Health
Bill and Melinda Gates Foundation · collabFogarty International Center of the National Institute of Health · collabGlobal Network for Women's and Children's Health Research · collabHealth Bureau Tibet Autonomous Region · collabNational Cancer Institute (NCI) · collabNational Center for Complementary and Integrative Health (NCCIH) · collabNational Institute of Dental and Craniofacial Research (NIDCR) · collabOne Heart Project · collabRTI International · collabUniversity of California, San Francisco · collabUniversity of Utah · collab
RandomizedParallel-groupDouble-blindPrevention
Summary
Previous research has confirmed that hemorrhage is among the most commonly encountered pregnancy complications in the Tibet Autonomous Region (TAR). This trial will test the effectiveness of a traditional Tibetan drug (Zhi Byed 11) vs. misoprostol to prevent postpartum hemorrhage (PPH) among women delivering vaginally in three hospitals in Lhasa, TAR.
Timeline
- Start
- 2005-09
- Primary completion
- —
- Completion
- 2007-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zhi Byed 11 | Traditional medicine (herbal / TCM) | — | Oral |